期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

髓性白血病的免疫调节和细胞免疫治疗研究进展 被引量：4

Advances in the immunoregulation and cellular immunotherapy in myeloid leukemia
下载PDF
导出
摘要 T细胞免疫状态与白血病病人抗白血病效应息息相关,在髓性白血病中,随着病情进展T细胞功能抑制更为明显。近年来,对于不同疾病不同阶段以及同种异型造血干细胞移植后复发病人,已形成了一些免疫治疗的新措施。本文主要介绍新近一些针对髓性白血病的特异免疫治疗包括过继性细胞免疫治疗以及可能的免疫调节治疗的研究进展。 T cell immune status is critic for maintaining anti-leukemia effect in leukemia patients.In patients with myeloid leukemia,T cell function becomes suppressed with disease progression.Several im-munotherapies have been developed for myeloid leukemia in different stages and relapse after allogeneic stem cell transplantation.In this review,several specific immunotherapeutic approaches for myeloid leu-kemia,including adoptive cellular immunotherapy and potential immunoregulation therapy are summa-rized.
作者 李扬秋 陈少华 査显丰
机构地区 暨南大学再生医学教育部重点实验室 暨南大学医学院血液病研究所 暨南大学 暨南大学附属第一医院临床检验中心
出处 《暨南大学学报（自然科学与医学版）》 CAS CSCD 北大核心 2013年第6期571-576,共6页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 国家自然科学基金项目(81100353,81270604) 广东省自然科学基金重点项目(S2013020012863) 中央高校基本科研业务费专项资金项目(21612116)
关键词 急性髓性白血病 慢性粒细胞性白血病 细胞毒T细胞 免疫抑制 免疫治疗 Acute myelogenous leukemia chronic myeloid leukemia cytotoxicity T cells im-mune suppression immunotherapy
分类号 R730.3 [医药卫生—肿瘤] R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献39

  • 1REAGAN J L, FAST L D, SAFRAN H, et al. Cellularimmunotherapy for refractory hematological malignancies[J]. J Transl Med, 2013,11(1) :150.
  • 2LICHTENEGGER F S,SCHNORFEIL F M,HIDDE-MANN W, et al. Current strategies in immunotherapy foracute myeloid leukemia [ J ]. Immunotherapy, 2013, 5(1):63 -78.
  • 3李扬秋.异基因免疫治疗促进移植物抗肿瘤效应的探讨[J].白血病．淋巴瘤,2012,21(1):3-5. 被引量：2
  • 4CHEN S, YANG L,CHEN S, et al. TCR zeta chain ex-pression in T cells from patients with CML[ J]. Hematol-ogy, 2009, 14(2) : 95 - 10.
  • 5闫小娟,查显丰,沈琦,等.慢性粒细胞白血病患者FceRIy链基因表达上调[J].暨南大学学报:医学版,2011,32(4):379 -382.
  • 6LI Y, GENG S, DU X,et al. Restricted TRBV reper-toire in CD4 + and CD8 + T-cell subsets from patientswith CML[ J] . Hematology, 2011, 16( 1 ) :43 -49.
  • 7LI Y, GENG S,YIN Q,et al. Decreased level of recentthymic emigrants in CD4 + and CD8 + T cells from pa-tients with CML[ J]. J Transl Med, 2010,8:47.
  • 8TORELLI GF,PAOLINI R,TATARELLI C, et al. De-fective expression of the T-cell receptor-CD3 zeta chain inT-cell acute lymphoblastic leukaemia [ J ]. Br J Haema-tol, 2003,120(2) :201 -208.
  • 92HA X,CHEN S,YANG L,et al. Up-regulated TCR^enhances interleukin-2 production in T-cells from patientswith CML[J]. DNA Cell Biol, 2012,31(11) : 1628 -1635.
  • 10CHEN J, SCHMITT A,CHEN B, et al. Imatinib impairsCD8 + T lymphocytes specifically directed against theleukemia-associated antigen RHAMM/CD168 in vitro[J]. Cancer Immunol Immunother,2007 , 56(6) :849 -861.

二级参考文献8

  • 1Porter DL. Allogeneic immunotherapy to optimize the graft-versustumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program,2001,2011:292-298.
  • 2Dennis M,Goodyea O,Loke J,et al.Azacitidine induces expansion of regulatory T cells and tumour specific CD +8 T lymphocytes after allogeneic stem cell transplantation: a strategy for epigenetic manipulation of a graft-versus-leukemia response. 2011 ASH Annual Meeting,Abstract 324.
  • 3Schuster S J,Hosing CM,Shpall EJ,et al.Adoptive immunotherapy with autologous CD3/CD28-costimulated T-cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. 2011ASH Annual Meeting,Abstract 2855.
  • 4Zhang M,Sukhumalchandra P,Enyenihi AA,et al.A novel HLA-A2 restricted peptide derived from cathepsing is an effective immunotherapeutic target for myeloid leukemia. 2011 ASH Annual Meeting,Abstract 2986.
  • 5Zohren F,Imperato MR,Usanarat A,et al.Genetic modification of multi leukemia antigen-specific cytotoxic T lymphocytes (CTL) to enhance in vivo safety and persistency. 2011 ASH Annual Meeting,Abstract 644.
  • 6Weber G,Gerdemann U,Hensel NF,et al.Generation of multi-antigen specific T cells for adoptive immunotherapy of myeloid leukemia and identification of MHC class Ⅰ and Ⅱ-restricted peptides for WT1,proteinase 3 and human neutrophil elastase. 2011 ASH Annual Meeting,Abstract 2985.
  • 7Hudecek M,Lupo-Stanghellini MT,Kosasih P,et al.Naive CD+4 T cells modified to express a ROR1-specific CAR mediate anti-tumor activity and provide superior help to CD+8 ROR1-CAR T cells. 2011 ASH Annual Meeting,Abstract 643.
  • 8Ochi T,Fujiwara H,Okamoto S,et al.Redirected CD+4 T cells using WT1-specific T-cell receptor gene transfer can supply multifactorial help to enhance the anti-leukemia reactivity mediated by similarly redirected CD+8 T cells using the identical gene transfer. 2011 ASH Annual Meeting,Abstract 645.

共引文献2

同被引文献22

引证文献4

二级引证文献19

暨南大学学报（自然科学与医学版）
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部